Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...
June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...
To earn CME related to this news article, click here. April 20, 2009 — A single 5-mg intravenous infusion of zoledronic acid was at least as effective and more acceptable to patients than 5 mg of oral ...
Zoledronic acid, while a bisphosphonate itself, is much more potent, and needs only to be given in a once-yearly infusion. In this randomised controlled trial, Professor David M Reid, University of ...
Please provide your email address to receive an email when new articles are posted on . Graeme Jones, PhD, and colleagues randomly assigned 223 patients with symptomatic knee OA and subchondral bone ...
The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...
Hyderabad: Gland Pharma Limited, a generic injectable and ophthalmic-focused pharmaceutical company, has received approval ...
Bisphosphonates are the most commonly used therapeutic agents for Paget's disease. Although bisphosphonates are effective in normalizing the biochemical markers that cause the erratic bone turnover ...
A proof-of-concept trial has shown that zoledronic acid is effective in preventing bone erosions in patients with early rheumatoid arthritis (RA). Zoledronic acid is a third-generation ...
The advent of bisphosphonates advanced therapy for Paget's disease, but more effective and convenient agents are needed to increase adherence. Zoledronic acid, a bisphosphonate administered as a ...
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results